Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)

N/ANo Longer AvailableNCT04173013

Impatients N.V. trading as myTomorrows

Overview

An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance.

UROMUNE® is a mucosal immunotherapy indicated for the prevention of urinary tract infections caused by different pathogens. It works by stimulating the immune system, thus increasing the resistance against recurrent infections. The active substances are 4 inactivated and selected bacterial strains: * Klebsiella pneumoniae 25% * Escherichia coli 25% * Enterococcus faecalis 25% * Proteus vulgaris 25%

Study Type

EXPANDED_ACCESS

Conditions

Urinary Tract Infections Chronic Urinary Tract Infection Recurrent Urinary Tract Infection Urinary Tract Infection Bacterial Bladder Infection

Interventions

UromuneBIOLOGICAL

2 sprays of solution once daily for a total of 3 months.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients suffering recurrent urinary tract infections of diverse etiology. Exclusion Criteria: * Individuals being allergic to any of the ingredients of UROMUNE®. * Pregnancy and breast feeding. There are neither specific studies nor a formal contraindication, the physician should value benefits/risk.

Locations (15)

Belgium

Brussels, Belgium

Czech Republic

Prague, Czechia

Denmark

Copenhagen, Denmark

Finland

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.